Loading clinical trials...
Loading clinical trials...
A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Neoadjuvant Chemotherapy
Conditions
Interventions
Durvalumab
Therapeutic Conventional Surgery
+1 more
Locations
1
United States
M D Anderson Cancer Center
Houston, Texas, United States
Start Date
March 7, 2017
Primary Completion Date
December 31, 2027
Completion Date
December 31, 2027
Last Updated
March 5, 2026
NCT06921733
NCT07126847
NCT06896149
NCT02007980
NCT04869462
NCT05087537
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions